Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Lysosomal Therapeutics
Lysosomal Therapeutics is a company dedicated to research and development in the field of neurodegeneration.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
iPierian
iPierian develops neurodegenerative disease therapies using induced pluripotent stem cell technology.
Sector
Subsector
Location
total rounds
total raised
Nextera AS
Nextera AS offers a versatile and innovative platform for developing novel therapeutic drugs.
Sector
Subsector
Keywords
Location
total rounds
Caraway Therapeutics
Rheostat Therapeutics is a bio therapeutics company that develops novel drugs to treat neurodegenerative diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds1
Number of Funding Rounds
Money Raised
Their latest funding was raised on 09.07.2020. Their latest investor Correlation Ventures. Their latest round Series A
Remiges Ventures
Remiges Ventures is a venture capital firm that focuses on investing in biopharma and life science startups, primarily in France.
Sector
Subsector
Keywords
Location
count Of Investments
SR One
SR One Capital Management is a biotech venture capital firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors5
Number of lead investors
Number of investors
Correlation Ventures
Correlation Ventures is a venture capital firm that finances early, seed, and later stage venture, and debt financing investments.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Remiges Ventures
Remiges Ventures is a venture capital firm that focuses on investing in biopharma and life science startups, primarily in France.
Sector
Subsector
Keywords
Location
count Of Investments
Taro Inaba
Mr. Inaba is Head of Global Bio-Pharma Team and Investment Partner at Mitsui Ventures responsible for investments in biotechnology and life science spaces both in the US and Asia. He has seventeen years experience in investments and business development both in life science and chemical industries. He serves as board member for Mitsui Ventures' three existing portfolio firms and responslbe for all 12 Mitsui Ventures biotechnology and life science portfolio firms. He holds a Bachelor of Engineering from Kyoto University and an MBA from European University in Lisbon. He is a CFA charter holder.
current job
SR One
SR One Capital Management is a biotech venture capital firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Rajeev Dadoo
Rajeev joined SR One in 2004 and is an alum of the Kauffman Fellows Program. Rajeev has been involved with SR Ones investments in Cydex, Hypnion, Predix Pharmaceuticals, Rib-X Pharmaceuticals, Octoplus, Trigen, Nucleonics, and Pinnacle Pharmaceuticals. In addition to his role at SR One, Rajeev spent time with the Competitive Excellence group within GSK working on company-wide strategic projects for GSKs Corporate Executive Team.
current job
People
Founders3
Chih-Ping Liu
Chih-Ping Liu is the Founder, Managing Director, and the Chairman of the Board of Directors at Angarus Therapeutics. He is also serving as a co-founder at Bolt Therapeutics. He received his Ph.D. degree in Genetics from the University of Wisconsin-Madison.
current job
organization founded
Chih-Ping Liu
Edgar G. Engleman
Dr. Edgar G. Engleman is the Member Of The Board Of Directors at Capia since 2001.He is a Founding Member of Vivo Ventures, LLC (formerly BioAsia Investments).Dr. Engleman is Professor of Pathology and Medicine at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, Dr. Engleman has authored more than 250 publications in medical and scientific journals and has trained more than 200 graduate students and postdoctoral fellows. He has co-founded a number of biopharmaceutical companies including Cetus Immune, Genelabs, National Medical Audit and Dendreon. He is the lead inventor of the technology underlying Provenge, Dendreon's cancer vaccine, which was shown to extend life for patients with metastatic prostate cancer with remarkably few side effects. Provenge is the first active immunotherapeutic agent to be approved by the FDA (in 2010).Dr. Engleman currently serves on the boards of several private biotechnology companies. He received his BA from Harvard University and his MD from Columbia University School of Medicine.
current job
Edgar G. Engleman